ANTIOXIDANT POTENTIAL OF PERITONEAL FLUID IN OVARIAN CANCER
Author:
Fedorova M.1, Voznesensky V.2, Sozarukova M.3, Kharchenko A.2, Sosnova E.4, Proskurnina E.5
Affiliation:
1. Central Research Institute for Epidemiology» of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing 2. Pletnev City Clinical Hospital of the Department of Health of Moscow 3. Kurnakov Institute of Gentral and Inorganic Chemistry of Russian Academy of Sciences 4. Sechenov University 5. Research Centre for Medical Genetics
Abstract
In ovarian cancer, peritoneal fluid is an active participant in carcinogenesis. The study included 48 patients aged 25–74 years with histologically confirmed ovarian cancer and benign ovarian neoplasms. Using an original technique based on the method of enhanced kinetic chemiluminescence, the antioxidant profiles of peritoneal fluid with ovarian cancer and benign neoplasms were evaluated. In the peritoneal fluid, the antioxidant capacity significantly increased in the series benign tumors > highly differentiated > moderately and poorly differentiated adenocarcinomas, leading to a state of antioxidant excess in the case of moderately and poorly differentiated adenocarcinomas. Thus, in ovarian cancer, tumor progression leads to a shift towards an excess of antioxidants, possibly due to metabolites of the tumor itself.
Publisher
RIOR Publishing Center
Reference45 articles.
1. Colombo N., Sessa C., du Bois A., Ledermann J., McCluggage W.G., McNeish I., Morice P., Pignata S., Ray-Coquard I., Vergote I. et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol., 2019, vol. 30, pp. 672-705, doi: 10.1093/annonc/mdz062., Colombo N., Sessa C., du Bois A., Ledermann J., McCluggage W.G., McNeish I., Morice P., Pignata S., Ray-Coquard I., Vergote I. et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol., 2019, vol. 30, pp. 672-705, doi: 10.1093/annonc/mdz062. 2. Webb P.M., Jordan S.J. Epidemiology of epithelial ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol., 2017, vol. 41, pp. 3-14, doi: 10.1016/j.bpobgyn.2016.08.006., Webb P.M., Jordan S.J. Epidemiology of epithelial ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol., 2017, vol. 41, pp. 3-14, doi: 10.1016/j.bpobgyn.2016.08.006. 3. Jayson G.C., Kohn E.C., Kitchener H.C., Ledermann J.A. Ovarian cancer. Lancet, 2014, vol. 384, pp. 1376-1388, doi: 10.1016/S0140-6736(13)62146-7., Jayson G.C., Kohn E.C., Kitchener H.C., Ledermann J.A. Ovarian cancer. Lancet, 2014, vol. 384, pp. 1376-1388, doi: 10.1016/S0140-6736(13)62146-7. 4. Moloney J.N., Cotter T.G. ROS signalling in the biology of cancer. Semin Cell Dev. Biol., 2018, vol. 80, pp. 50-64, doi: 10.1016/j.semcdb.2017.05.023., Moloney J.N., Cotter T.G. ROS signalling in the biology of cancer. Semin Cell Dev. Biol., 2018, vol. 80, pp. 50-64, doi: 10.1016/j.semcdb.2017.05.023. 5. Aggarwal V., Tuli H.S., Varol A., Thakral F., Yerer M.B., Sak K., Varol M., Jain A., Khan M.A., Sethi G. Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules, 2019, vol. 9, doi: 10.3390/biom9110735., Aggarwal V., Tuli H.S., Varol A., Thakral F., Yerer M.B., Sak K., Varol M., Jain A., Khan M.A., Sethi G. Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules, 2019, vol. 9, doi: 10.3390/biom9110735.
|
|